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Table I
Etiology of re-admission
Reason for admission Events
Documented infection 95 (34%)
GVHD 58 (21%)
Unexplained fever 58 (21%)
Relapse 29 (10%)
Gastrointestinal symptoms 28 (10%)
Other 8 (2%)
Total events 276
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Background: Although small studies have linked poor
nutritional status pre-hematopoietic stem cell transplant
(HSCT) to metabolic derangements post-HSCT, no large study
has studied the inﬂuence of nutritional support initially after
HSCT on clinical outcomes. We hypothesized that better
enteral (EN) or parenteral nutrition (PN) before and peri-
HSCT would correlate with improved nutritional status and
fewer complications after HSCT including graft-versus-host
disease (GVHD). We conducted a multi-institutional, IRB
approved retrospective study to compare the nutritional
status of patients who received EN, PN, or suboptimal
nutrition in the week before and the ﬁrst 4 weeks post-HSCT
using a novel nutritional summary score.
Method: We devised the nutrition summary score by
assigning a number from 0-2 (0¼no/poor EN/PN, 1¼PN for
goal calories, and 2¼EN for majority of goal) weekly for the 5
weeks (-1, 1, 2, 3, 4) per patient; the scores were summed
(total summary score ranged from 0-10). Nutritional assess-
ments and outcomes were abstracted from medical records
at day 28, day 100, and 1 year after HSCT.
Results: Data were captured from 162 patients (78%
pediatric and 22% adult) from 5 institutions. Patients were a
median age of 10.34 years (range: 1-75), 58% male, and 75%
received myeloablative, 17% reduced intensity, and 8% non-
myeloablative HSCT. At the pre- and peri-HSCT period, few
patients had gastric tubes (6/162) but 44% (72/162) had
nasogastric tubes for EN. Themajority (89%) engrafted by day
+28, and GVHD rates reﬂect the predominance of pediatric
patients with only 14% (22/162) grade I-II acute GVHD
(aGVHD), 17% (27/162) grade III-IV aGVHD, 10% (17/162)
limited chronic, and 10% (16/162) chronic extensive GVHD.
Mean summary nutrition scores and % EN for each time point
were: pre-BMT: 1.42 and 70% EN, week 1: 1.41 and 64%,
week 2: 1.3 and 52%, week 3: 1.3 and 54%, and week 4 1.3 and
58%. The day +28 albumin was correlated directly with the
summary nutrition score (p<0.0001). The weight 100
days after HSCT was also associated with summary
nutritional score (p¼0.017), while chronic extensive GVHD
was associated with lower nutrition score (p¼0.047). Using
only patients who received EN at some point (at least one
value of 2 in the 5 weeks), weight at day 28 (p¼0.002) and
day 100 (p<0.002), and lower risk of cGVHD (p< 0.04) all
were signiﬁcant, suggesting that EN contributed to these
outcomes.
Conclusions: Our data suggest that EN and PN in the pre-
and peri-HSCT period correlate with better nutrition after
HSCT including albumin at day +28 and weight at day +100
and that these may inﬂuence risk for chronic extensive
GVHD, a major complication of HSCT. Further, our data
suggest that EN initially after HSCT may be important,
and support a prospective study to evaluate whether
interventions to improve enteral alimentation enhance
outcomes and diminish the risk of chronic extensive GVHD.344
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Introduction: Hematopoietic stem cell transplantation
(HSCT) provides potential curative treatment for various
benign and malignant conditions. However, there is a high
rate of patients requiring readmission to the hospital within
six months of transplantation. There is only limited literature
evaluating risk factors and causes of readmission of children,
adolescents and young adults (AYA) who underwent HSCT.
Materials and Methods: A retrospective analysis of patients
aged  26 years treated at University of Texas MD Anderson
Cancer Center with HSCT was conducted using descriptive
measures.
Results: A retrospective chart review of 435 transplants in
pediatric and AYA patients from the period of 2008 to 2013
revealed that 161 (37%) patients had at least one hospital
readmission within 180 days of transplant. Ninety-ﬁve
patients were male. The median age at transplant was 21
(range 1-26) years. Primary diagnoses were as follows: he-
matologic malignancy (n¼115), solid tumor (n¼32), and
non-malignant conditions (n¼17). Lansky or Karnofsky
function levels were at a median of 90% at the time of
transplant. Amongst patients readmitted, 87% of patients
received allogeneic HSCT and 13% had autologous HSCT. The
median number of readmissions per patient was 2 (range
1-6). Twenty-nine (18 %) patients were transplanted more
than one time including 4 patient readmits as part of tandem
transplant. Forty-three (29%) patients with solid and
hematological malignancies were not in remission at time of
transplant. A total of 276 readmission events were reported
in the study. The etiology of readmission was multifactorial,
and the event etiologies are summarized in Table I. At a
median follow up of 23.5 months (range 0.2-72), 88 of 161
readmitted patients remain alive. Causes of death were due
to disease recurrence (n¼46) and transplant related
mortality (n¼ 27).
Discussion: This is the largest reported pediatric and young
adult cohort reporting the etiology of readmission within 6
months after HSCT. The highest cause of readmission was
documented infection. Disease relapse contributed to the
high mortality of these patients. We aim to deﬁne a risk
standardized approach to decrease hospital readmissions
post HSCT, identify a low risk group of patients and devise
intervention(s) that reduce the rate of readmissions.345
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Table 1
Patient Characteristics
No CRT CRT +
Anticoagulation
CRT with no
anticoagulation
Number of patients 190 11 13
Median age at transplant
(year)
58 62 60
Male gender 116 6 10
Ethnicity:
Caucasian 122 7 12
African 47 2 1
Asian 7 0 0
Hispanic 6 2 0
Other/Unknown 8 0 0
Malignancy:
Myeloma 132 8 8
Non-Hodgkin’s lymphoma 34 2 3
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Introduction: Pain following hematopoietic stem cell
transplantation (HSCT) is caused by several factors: chemo-
therapy, radiotherapy, infections, GVHD, and medications.
Difﬁculties in deﬁning and accurately diagnosing pain
symptoms can lead to delays in starting effective analgesia
and poorer quality of life. Pain syndromes following HSCT
have not been well-studied and the actual prevalence is
unknown. The goal of this study was to determine incidence,
severity, and the time course of pain following HSCT.
Method: We designed a prospective, observational study
which enrolled 100 patients undergoing HSCT (60%
autologous, 40% allogeneic. 19 unrelated, 13 sibling, 8 double
cord. Myeloma 44%, leukemia 29%, lymphomas 26%, and
aplastic anemia 1%). Patients enrolling on the study
completed 5 questionnaires before HSCT and 1, 2, 3, 6, 9,
and 12 months after HSCT. The questionnaires were the
Brief Pain Inventory (BPI), the EORTC Quality of Life
Questionnaire-Chemotherapy Induced Peripheral Neuropa-
thy (EORTC-CIPN), the Muscle and Joint Measure (MJM), the
MD Anderson Symptom Index e Graft-versus-Host Disease
module (MDASI-cGVHD), and the Hospital Anxiety and
Depression Scale (HADS).
Results: At the 9-month review, we found that there was a
signiﬁcant increase in pain reported after allogeneic HSCT
compared to pre-HSCT. (71% increase at 3 months; p¼0.01).
This difference was independent of conditioning regimen,
disease or GVHD. For autologous HSCT, there was an increase
in reported neuropathic symptoms (47% increase at 3
months; p¼0.02). We also found and increase in muscle
cramping and spasms late after HSCT; both autologous and
allogeneic (99% increase at 9 months; p¼0.03). Muscle
cramping interfered with sitting, standing and physical
activity (21% at 6 months; p¼0.04 and 136% at 9 months;
p¼0.04). The increase in muscle cramping symptoms was
independent of conditioning regimen, disease or GVHD.
Conclusions: Our current review of this study reveals that
pain and muscle cramping is a signiﬁcant symptom that
develops after both allogeneic and autologous HSCT. This
appears to be independent of conditioning regimen, disease
or GVHD.Hodgkin’s lymphoma 12 0 0
Primary amyloidosis 3 1 2
CLL 2 0 0
AML 2 0 0
APML 1 0 0
Other 4 0 0
Conditioning:
Melphalan alone 135 9 10
BEAM 48 2 3
Busulfan/Cyclophosphamide 2 0 0
Cyclophosphamide alone 4 0 0
Unknown 1 0 0
Neutrophil engraftment
(in days)
11 12 12
Platelet engraftment
(in days)
15 17 17
Table 2
Outcome analysis
No CRT CRT +
Anticoagulation
CRT with no
anticoagulation
p-
value
Platelet utilization
(Number of pooled
platelet units)
4 14 4 0.02
PRBC cell utilization
(Number of PRBC
transfusions)
2 4 2 0.01346
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Introduction: The optimal management of catheter-related
thrombosis (CRT) in patients undergoing autologous
stem-cell transplantation (ASCT) remains poorly deﬁned. We
reviewed the management of catheter-related thrombosis in
ASCT patients in our transplant unit over an 8-year period.Methods: We reviewed all patients undergoing ASCT at
Thomas Jefferson University from 2006-2013. Patients with
previous history of venous thrombosis receiving anti-
coagulation at ASCT were excluded. Patients with CRT were
identiﬁed andmanagementwas reviewed. Three populations
were identiﬁed: No CRT, CRT no anticoagulation, and CRT on
anticoagulation. We performed a Wilcoxon Ranks Sum anal-
ysis to evaluate blood and platelet utilization in the three
groups. We also reviewed major bleeding events (MBE) and
secondary thrombotic events (pulmonary embolism, PE).
Results: We identiﬁed 214 patients as described in Table 1.
The incidence of CRT for the whole group was 11.2%. Of the
24 patients with CRT, 46% were treated with AC and the
remaining was observed without AC. The median number of
pooled platelets transfused was 14 in the CRT + AC group, 4
in the no CRT and 4 CRT with no anticoagulation groups
(p¼0.02). The median number of PRBC transfusions in the
no CRT, CRT + AC, and CRT with no AC groups was, 2, 4, and
2, respectively (p¼0.01). None of the patients with CRT
developed a second thrombotic event (PE). Incidence of
major bleeding within the CRT + AC group was 27% while in
the CRT and no AC group was 15% (p¼NS). One patient
expired due to the result of a subarachnoid hemorrhage.
Conclusions: A strategy utilizing AC for CRT in the setting of
an autologous transplant results in increased utilization of
both platelet and PRBC transfusion and is associated with a
trend towards a higher risk of major bleeding. There was no
